Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study

References

• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Eng J Med 1998;339:321-8
   PubMed Web of Science ®Google Scholar
• Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999;134:437-44
   PubMed Web of Science ®Google Scholar
• Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive aminoterminal pro-brain natriuretic peptide (NT-PROBNP): a new marker for cardiac impairment. Clin Endocrinol 1997;47:287-96
   PubMed Web of Science ®Google Scholar
• Struthers AD. How to use natriuretic peptide levels for diagnosis and prognosis. Eur Heart J 1999;20:1374-5
   PubMed Web of Science ®Google Scholar
• Talwar S, Squire IB, Cavies JE, et al. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J 1999;20:1736-44
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75
   PubMed Web of Science ®Google Scholar
• Ndrepepa G, Braun S, Niemoller K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation 2005;112:2102-7
   PubMed Web of Science ®Google Scholar
• Schnabel R, Rupprecht HJ, Lackner KJ, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005;26:241-9
   PubMed Web of Science ®Google Scholar
• Fisher C, Berry C, Blue L, et al. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003;89:879-81
   PubMed Web of Science ®Google Scholar
• Doust JA, Pietrzak E, Dobson A, et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005;330:1-9
   PubMedGoogle Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9:S16-23
   PubMed Web of Science ®Google Scholar
• Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745-53
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Benedetto A, et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12:1508-15
   PubMed Web of Science ®Google Scholar
• Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84
   PubMed Web of Science ®Google Scholar
• Khan IA, Fink J, Nass C, et al. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006;97:1530-4
   PubMed Web of Science ®Google Scholar
• Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007;50:1009-19
   PubMed Web of Science ®Google Scholar
• Spanaus KS, Kronenberg F, Ritz E, et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 2007;53:1264-72
   PubMed Web of Science ®Google Scholar
• Winkler K, Wanner C, Drechsler D, et al. Change in N-terminal-pro-B-type-natriuretic- peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008;29:2092-9
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci 2005;108:23-36
   PubMed Web of Science ®Google Scholar
• Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-15
   PubMed Web of Science ®Google Scholar
• Austin WJ, Bhalla V, Hernandez-Acre I, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006;126:506-12
   PubMed Web of Science ®Google Scholar
• Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kid Dis 2005;46:610-20
   PubMed Web of Science ®Google Scholar
• Olsson LG, Swedberg K, Cleland JG, et al. Prognostic importance of plasma NT-proBNP in chronic heart failure patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 2007;9:795-801
   PubMed Web of Science ®Google Scholar
• Bruch C, Reinecke H, Stypmann J, et al. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure. J Heart Lung Transplant 2006;25:1135-41
   PubMed Web of Science ®Google Scholar
• deFilippi CR, Fink JC, Nass CM, et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 2005;46:35-44
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Gomez-Campdera F, et al. Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int Suppl 2005;93:S35-38
   Google Scholar
• Hase H, Tsunoda T, Tanaka Y, et al. Risk factors for de novo acute cardiac events in patients initiating haemodialysis with no previous cardiac symptom. Kidney Int 2006;70:1142-8
   PubMed Web of Science ®Google Scholar
• Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003;16:101-5
   PubMed Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anaemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 2005;16:1803-10
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand I, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006;52:1528-38
   PubMed Web of Science ®Google Scholar